Truist Securities Maintains Hold on ANI Pharmaceuticals, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on ANI Pharmaceuticals while raising the price target from $60 to $62.
October 22, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has maintained a Hold rating on ANI Pharmaceuticals and increased the price target from $60 to $62, indicating a slightly positive outlook.
The increase in price target from $60 to $62 by Truist Securities suggests a slightly positive outlook for ANI Pharmaceuticals. However, the Hold rating indicates that the stock is expected to perform in line with the market, which may not lead to significant short-term price movements.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100